Vitamin B3 Shows Promise Against Fatty Liver Disease in New Research
Scientists discover vitamin B3 can target a key genetic driver of fatty liver disease, offering hope for a safe, accessible treatment.
Summary
Researchers have identified a breakthrough in treating fatty liver disease, which affects 30% of people worldwide. Scientists at UNIST discovered that microRNA-93 is a key genetic factor that drives fat buildup and inflammation in the liver. More importantly, they found that vitamin B3 (niacin) can effectively shut down this harmful genetic activity. In mouse studies, vitamin B3 treatment reduced fat accumulation in the liver and improved overall liver function by restoring normal fat-processing pathways. This discovery is significant because vitamin B3 is already FDA-approved, widely available, and has a well-established safety profile for treating high cholesterol.
Detailed Summary
A groundbreaking study has identified vitamin B3 as a potential treatment for metabolic-associated fatty liver disease (MASLD), a condition affecting roughly 30% of people globally with few effective therapies. Researchers at UNIST, working with teams from Pusan National University and Ulsan University Hospital, discovered that microRNA-93 (miR-93) serves as a central regulator in fatty liver disease development.
The research team found that miR-93 levels are abnormally high in both human patients and animal models with fatty liver disease. This small RNA molecule disrupts liver function by suppressing SIRT1, a crucial gene that manages fat metabolism in liver cells. When researchers used gene editing to eliminate miR-93 production in mice, the animals showed significantly less liver fat accumulation, improved insulin sensitivity, and better overall liver function.
The most promising discovery came when scientists screened 150 FDA-approved drugs to find treatments that could reduce miR-93 levels. Vitamin B3 (niacin) emerged as the most effective option, dramatically lowering miR-93 levels while increasing beneficial SIRT1 activity in treated mice. This restored normal fat-processing pathways and improved lipid balance throughout the liver.
The clinical implications are significant because vitamin B3 is already approved, widely available, and has a proven safety record for treating high cholesterol. The researchers suggest it could be repurposed for combination therapies targeting fatty liver disease, potentially offering millions of patients a safe, accessible treatment option where few currently exist.
Key Findings
- MicroRNA-93 identified as key genetic driver of fatty liver disease progression
- Vitamin B3 effectively reduces harmful miR-93 levels and restores liver function in mice
- Gene editing to eliminate miR-93 significantly reduced liver fat and improved metabolism
- Vitamin B3 treatment restored normal fat-processing pathways in diseased livers
- This represents first clear link between miR-93 and fatty liver disease development
Methodology
This is a research news report from ScienceDaily covering peer-reviewed research published in Metabolism: Clinical and Experimental. The study involved both human tissue analysis and controlled animal experiments using gene editing techniques. The research was conducted by established institutions including UNIST and supported by Korean national research foundations.
Study Limitations
The study was primarily conducted in mouse models, and human clinical trials have not yet been performed to confirm efficacy and optimal dosing. The article doesn't specify the vitamin B3 doses used or potential side effects at therapeutic levels. Primary research should be consulted for detailed methodology and statistical significance of results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.